Intracranial disease control for EGFR-mutant and ALK-rearranged lung cancer with large volume or symptomatic brain metastases

Tyrosine kinase inhibitors (TKIs) are commonly employed for patients with brain metastases from lung
cancer and specific driver mutations. We sought to identify the correlation between intracranial tumor
burden and outcomes in patients with brain metastases treated with TKIs.... Most patients receiving TKIs
as part of their initial therapy achieve an early and durable volumetric intracranial response, irrespective of
presenting disease burden or neurologic symptoms. READ ARTICLE

Journal of Neuro-Oncology volume DOI:10.1007/s11060-020-03615-4

Authors: Sunil W. Dutta, Marie L. Mack, Eric Aliotta, Kristin A. Ward, Donald A. Muller, James M. Larner, Camilo E. Fadul, Richard D. Hall, Ryan D. Gentzler, Jason P. Sheehan